COMMUNIQUÉS West-GlobeNewswire

Diaxonhit - Chiffre d'affaires 2017 à 42,9 M€, en très forte progression de 55%

29/01/2018 - 18:48

Chiffre d'affaires 2017 à 42,9 M€, en très forte progression de 55% Chiffre d'affaires pro forma à 48,0 M€ en progression de 9% Paris, le 29 janvier 2018 - Diaxonhit (FR0013240934, ALEHT, éligible PEA-PME), groupe [...]

OnePoint Patient Care Launches OneConnectPoint

29/01/2018 - 18:35

MORTON GROVE, Ill., Jan. 29, 2018 (GLOBE NEWSWIRE) -- OnePoint Patient Care has introduced OneConnectPoint, the hospice industry’s most advanced medication management application. Specifically designed to meet the [...]

IBA SA : Transparence notification

29/01/2018 - 18:00

IBA - TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, January 29, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that [...]

IBA SA : Notification de transparence

29/01/2018 - 18:00

IBA - NOTIFICATION DE TRANSPARENCE Louvain-la-Neuve, Belgique, 29 janvier 2018, 17.35 - IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce [...]

Sanofi: Disclosure of trading in own shares

29/01/2018 - 17:46

Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/6e41672b-0d81-4b18-9200-48dfaee5babb

Sanofi : Déclaration des transactions sur actions propres

29/01/2018 - 17:46

Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/c8d27e2e-859c-40f7-9b2c-ea4b2c7d0c71

Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB

29/01/2018 - 17:29

Company announcement Orphazyme A/S No. 02/2018 Copenhagen, Denmark, January 29, 2018 – Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, [...]

Pressure BioSciences, Inc. CEO, Ric Schumacher, Rejoins “Stock Day”, Very Optimistic About His Company’s Growth and Success in 2018 and Beyond

29/01/2018 - 17:09

PHOENIX, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Mr. Richard T. Schumacher, CEO and President of Pressure BioSciences, Inc. (OTCQB:PBIO) (the “Company”) returns to the “Stock Day” podcast for the first time since the Company’ [...]

ProCare Pain Solutions Publishes New Research Exploring Effects of Fibromyalgia on Chronic Pain Population

29/01/2018 - 17:04

MELVILLE, N.Y., Jan. 29, 2018 (GLOBE NEWSWIRE) -- ProCare Pain Solutions , a division of North American Partners in Anesthesia (NAPA) announced today that an innovative research study it conducted in 2016 and 2017 has [...]

Ossur Hf : Transactions in relation to share buyback program

29/01/2018 - 17:01

Announcement from Össur hf. No. 6/2018 Reykjavík, 29 January 2018 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent

29/01/2018 - 16:44

COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’ [...]

Scapa Healthcare Introduces Low Trauma Hydrocolloid Adhesive for Sensitive Skin Applications

29/01/2018 - 16:00

WINDSOR, Conn., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Scapa Healthcare, a leading strategic outsource partner of skin friendly turn-key solutions, today announced the availability of Scapa Soft-Pro® Low Trauma Hydrocolloid [...]

Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

29/01/2018 - 15:30

REDWOOD CITY, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock at a public [...]

US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella

29/01/2018 - 15:20

Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok [...]

Advantis Corp Expanding Into Colorado, California Nears Packaging Capacity With New Machine; Pre Orders for New Sizes Escalate Quickly

29/01/2018 - 15:15

NEWPORT BEACH, CA , Jan. 29, 2018 (GLOBE NEWSWIRE) -- ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it is finalizing an agreement to provide Amster-Can and other Advantis branded products to a licensed [...]

NYC Plastic Surgeon Cautions Against Winter Binge Tanning And Its Damaging Effects

29/01/2018 - 15:00

New York, New York, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Dr. Darrick E. Antell , a top plastic surgeon in NYC, warns against the damaging effects the sun can have when traveling in the winter months due to a phenomenon [...]

InstaLipo™ Reduces Stubborn Fat Non-Surgically!

29/01/2018 - 15:00

New York City, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Are you struggling to lose those extra inches off your waist, hips, thighs, or buttocks? NYC plastic surgeon Dr. Sharon Giese is now offering InstaLipo™ – the latest non- [...]

Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial

29/01/2018 - 15:00

LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the human gut microbiome to treat [...]

Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases

29/01/2018 - 15:00

BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update: The Confidential [...]